RENB: Renovaro Inc. Stock

by  •  • Comments Off on RENB: Renovaro Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 57.63
Enterprise Value ($M) 63.27
Book Value ($M) 82.06
Book Value / Share 0.51
Price / Book 0.70
NCAV ($M) -27.57
NCAV / Share -0.17
Price / NCAV -2.09

Profitability (mra)
Return on Invested Capital (ROIC) -1.33
Return on Assets (ROA) -0.56
Return on Equity (ROE) -0.70

Liquidity (mrq)
Quick Ratio 0.06
Current Ratio 0.06

Balance Sheet (mrq) ($M)
Current Assets 1.71
Assets 111.34
Liabilities 29.28
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
6 days ago 13D/A William Anderson Wittekind 10.40 -1.89

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-19 10-K/A United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under s
2025-02-19 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2025-02-19 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2025-02-19 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2024-11-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-28 10-K/A United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under sec
2024-10-10 10-K United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under section 13 Or 15(d) o
2024-08-20 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-05-15 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 1

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 67,758 357,504 18.95
2025-04-16 90,343 485,122 18.62
2025-04-15 52,586 481,493 10.92
2025-04-14 193,045 1,071,005 18.02

(click for more detail)

Similar Companies
PULM – Pulmatrix, Inc. QLGN – Qualigen Therapeutics, Inc.
QTTB – Q32 Bio Inc. REVB – Revelation Biosciences, Inc.
RGC – Regencell Bioscience Holdings Limited


Financial data and stock pages provided by
Fintel.io